Abstract
In this review, we focus on the chemicals used in the current treatment of type 2 diabetes and discuss some potentially viable, promising targets in the management of this metabolic syndrome, with a special mention to some naturally occurring bioactive compounds. Non insulin dependent diabetes mellitus (NIDDM or Type 2 diabetes) is a prevalent, chronic metabolic disorder, which affects more than 171 million people worldwide. Diminished insulin secretion due to impaired cell function and or insulin resistance of the peripheral tissues such as liver, adipose tissue and skeletal muscle causes hyperglycemia, which is controlled with suitable pharmacological agents. The current line of treatment includes: (1) insulin secretagogues, (2) insulin sensitizers, (3) dipeptidyl peptidase IV inhibitors, (4) biguanides, (5) glucosidase inhibitors and (6) drugs in development.
Keywords: Oral Hypoglycemics, metabolic syndromeNon insulin dependent diabetes mellitus (NIDDM), chronic metabolic disorder, hyperglycemia, insulin sensitizers, biguanides
Current Bioactive Compounds
Title: Oral Hypoglycemics: A Review of Chemicals Used to Treat Type 2 Diabetes
Volume: 4 Issue: 2
Author(s): S. W. Zito, J. Shinde, I C. S. Chen, T. Taldone and M. Barletta
Affiliation:
Keywords: Oral Hypoglycemics, metabolic syndromeNon insulin dependent diabetes mellitus (NIDDM), chronic metabolic disorder, hyperglycemia, insulin sensitizers, biguanides
Abstract: In this review, we focus on the chemicals used in the current treatment of type 2 diabetes and discuss some potentially viable, promising targets in the management of this metabolic syndrome, with a special mention to some naturally occurring bioactive compounds. Non insulin dependent diabetes mellitus (NIDDM or Type 2 diabetes) is a prevalent, chronic metabolic disorder, which affects more than 171 million people worldwide. Diminished insulin secretion due to impaired cell function and or insulin resistance of the peripheral tissues such as liver, adipose tissue and skeletal muscle causes hyperglycemia, which is controlled with suitable pharmacological agents. The current line of treatment includes: (1) insulin secretagogues, (2) insulin sensitizers, (3) dipeptidyl peptidase IV inhibitors, (4) biguanides, (5) glucosidase inhibitors and (6) drugs in development.
Export Options
About this article
Cite this article as:
Zito W. S., Shinde J., Chen S. I C., Taldone T. and Barletta M., Oral Hypoglycemics: A Review of Chemicals Used to Treat Type 2 Diabetes, Current Bioactive Compounds 2008; 4 (2) . https://dx.doi.org/10.2174/157340708785294190
DOI https://dx.doi.org/10.2174/157340708785294190 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CoMFA Study on Thiazolidine-2,4-diones for their Antihyperglycemic Activity
Letters in Drug Design & Discovery Recent Developments in Patents Targeting Toll-Like Receptor Genes
Recent Patents on DNA & Gene Sequences Diet, Cardiometabolic Factors and Type-2 Diabetes Mellitus: The Role of Genetics
Current Diabetes Reviews Herbal Drug use in Sickle Cell Disease Management; Trends and Perspectives in Sub-Saharan Africa - A Systematic Review
Current Drug Discovery Technologies Why Antidiabetic Vanadium Complexes are Not in the Pipeline of “Big Pharma” Drug Research? A Critical Review
Current Medicinal Chemistry 30 Years Lost in Anesthesia Theory
Cardiovascular & Hematological Agents in Medicinal Chemistry Epigenetic control of cardiovascular health by nutritional polyphenols involves multiple chromatin-modifying writer-reader-eraser proteins
Current Topics in Medicinal Chemistry Adrenomedullin: Exciting New Horizons
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Meet Our Section Editor
CNS & Neurological Disorders - Drug Targets Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles
Recent Patents on Drug Delivery & Formulation Insulin- and Growth Factor-Resistance Impairs Vascular Regeneration in Diabetes Mellitus
Current Vascular Pharmacology Early Life and Oxidative Stress in Psychiatric Disorders: What Can we Learn From Animal Models?
Current Pharmaceutical Design The Universal Nature, Unequal Distribution and Antioxidant Functions of Melatonin and Its Derivatives
Mini-Reviews in Medicinal Chemistry Nicotine Addiction and Coronary Artery Disease: Impact of Cessation Interventions
Current Pharmaceutical Design Metabolic Syndrome and Non-Cardiac Vascular Diseases: An Update from Human Studies
Current Pharmaceutical Design Transforming Growth Factor-Beta and the Kidney: What We Know and What We Can Do?
Current Enzyme Inhibition How to Advise Aspirin Use in Patients Who Need NSAIDs
Current Pharmaceutical Design The Impact of Infection on the Incidence of Autoimmune Disease
Current Topics in Medicinal Chemistry Pharmacotherapy of Obesity - Benefit, Bias and Hyperbole
Current Medicinal Chemistry Prevalence and associated factors of sarcopenia in elderly subjects with amnestic mild cognitive impairment or Alzheimer disease.
Current Alzheimer Research